Dicot Pharma AB Logo

Dicot Pharma AB

DICOTBT | SPGR

Overview

Corporate Details

ISIN(s):
SE0011178458 (+1 more)
LEI:
549300GX132RSE4OV407
Country:
Sweden
Address:
St Olofsgatan 11A, 753 21 Uppsala
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Dicot Pharma AB is a pharmaceutical company focused on developing the next generation of potency drugs. Its lead drug candidate, LIB-01, is in development for the treatment of erectile dysfunction and premature ejaculation. The company's objective is for LIB-01 to offer significant advantages over existing therapies, including a longer duration of effect, fewer side effects, and efficacy for a broader patient population. Dicot Pharma aims to establish LIB-01 as a first-choice treatment globally, addressing the needs of the over 500 million men worldwide affected by these conditions.

Social Media

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for Dicot Pharma AB. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Dicot Pharma AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Dicot Pharma AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-09-12 Tullbacken Aktiebolag Other Buy 35,000 40,250.00 SEK
2024-09-10 Amandus Jabin Other Sell 110,000 4,276,800.00 SEK
2024-09-03 Jörgen Larsson Other Other 315,000 N/A
2024-09-02 Patrick Lawlor Other Buy 77,500 1,158,625.00 SEK
2024-09-02 Oskar Hellström Other Buy 75,000 1,121,250.00 SEK
2024-09-02 Martin Walfisz Other Other 2,108,718 442,830.78 SEK
2024-08-31 Bonny Heeren Other Other 5,000,000 550,000.00 SEK
2024-08-30 Per-Anders Hedin Other Other 5,000,000 110,000.00 SEK
2024-08-30 Erik Markus Näsholm Other Other 2,000,000 42,600.00 SEK
2024-08-30 Greger Larsson Other Other 1,600,000 34,080.00 SEK

Peer Companies

Company Country Ticker View
Genmab Logo
Develops antibody therapeutics for cancer and serious diseases using proprietary technology.
Denmark GMAB
Genomic Vision Logo
Develops DNA analysis tools using Molecular Combing for genetic research and diagnostics.
France GV
genOway Logo
Develops genetically engineered preclinical models for biopharma and academic research.
France ALGEN
GenSight Biologics S.A. Logo
Biopharma developing gene therapies for retinal neurodegenerative diseases and CNS disorders.
France SIGHT
Genxone Spolka Akcyjna Logo
A biotech firm offering nanopore DNA/RNA sequencing services and medical diagnostics.
Poland GX1
Guard Therapeutics International AB Logo
Clinical-stage biotech developing protein-based therapies for acute kidney injury.
Sweden GUARD
Gubra A/S Logo
Preclinical CRO and peptide drug developer for metabolic and fibrotic diseases.
Denmark GUBRA
Hamlet BioPharma AB Logo
Developing selective therapies for cancer and infections like bladder cancer and UTIs.
Sweden HAMLET
HEMOGENYX PHARMACEUTICALS PLC Logo
Develops novel therapies for life-threatening blood disorders, cancers, and autoimmune diseases.
United Kingdom HEMO
Herantis Pharma Oyj Logo
Clinical-stage biotech developing therapies for neurodegenerative disorders like Parkinson's.
Finland HRTIS